FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum...

Related Keywords

United States ,New Jersey ,East Hanover ,America ,Graham Jm Jr ,Julie Masow ,Kristen Davis ,Sloan Simpson ,Victor Bulto ,Dan Connelly ,Guillaume Canaud ,Novartis Oncology Patient Support Program ,Twitter ,Novartis ,Compassionate Use Programme ,University Of Washington ,Syndrome Community ,Paris Descartes University ,Institute Necker Enfants Malades ,National Institutes Of Health ,Drug Administration ,Novartis Oncology Communications ,Exchange Commission ,Approval Program ,Novartis Pharmaceuticals Corporation ,Nj Novartis Pharmaceuticals Corporation ,Novartis Pharmaceuticals Corp ,Centre For Molecular Medicine ,Related Overgrowth Spectrum ,Accelerated Approval Program ,Multichannel News Release ,Executive Director ,Necker Enfants Malades Hospital ,Necker Enfants Malades ,Molecular Medicine ,Novartis Innovative Medicines ,Patient Novartisoncology ,National Institutes ,Prescribing Information ,Pharmaceuticals Corporation ,Retrospective Chart Review Study ,Patients With ,Compassionate Use ,Pharmaceuticals Corp ,Media Relations ,